Nicardia

Quick links to important sections

Nicardia

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nicardia

Quick Facts

Property Description
Active Ingredient Nifedipine
Form Tablet, extended-release tablet, capsule
Pharmacological Class Calcium Channel Blocker (Dihydropyridine derivative)
General Purpose Managing blood pressure and easing cardiovascular strain
Origin Synthetic drug

What is Nicardia? Defining the Core Identity

Nicardia is a prescription medicine whose core active ingredient is Nifedipine, a synthetic compound that is clinically recognized for its efficacy in cardiovascular management. This medication is typically delivered through the oral route and is available in multiple forms, including a conventional tablet, a specialized extended-release tablet, or a capsule, allowing for different administration profiles. Nifedipine is classified as a single-ingredient product, structured as a derivative of the dihydropyridine chemical family. The use of the extended-release tablet is a distinguishing feature, designed to provide a sustained, consistent release of the active ingredient over time, which is favored for the long-term management of chronic cardiovascular conditions.


Nifedipine's Pharmacological Class and General Purpose

Nifedipine is scientifically classified as a Calcium Channel Blocker (CCB). This places it in a category of drugs that influence the movement of calcium within certain body cells. This classification means the drug's fundamental function is to modulate the calcium ion influx into the muscle cells of the blood vessels, leading to vascular relaxation or vasodilation. This drug category is foundational for managing circulatory health by lowering resistance in the blood vessels and improving blood flow.

This mechanism reduces the force, known as peripheral vascular resistance, that the heart must overcome to pump blood throughout the body. The general purpose of this action is to lower overall blood pressure and relieve chronic strain on the cardiovascular system by facilitating easier blood flow through the opened arteries.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Nicardia?

Possible Side Effects and Safety Information

Official regulatory documents classify the possible adverse effects of Nifedipine (Nicardia) based on how frequently they are reported and the System-Organ Class (SOC) affected. Effects are often linked to the drug's vasodilatory action.

Frequency-Classified Adverse Reactions

The most commonly documented effects are related to the cardiovascular and nervous systems, often presenting as vasodilatory symptoms:

Classification Examples of Documented Effects
Very Common (ge 10%) Flushing (heat sensation), Oedema (Peripheral Edema)
Common (ge 1% to < 10%) Headache, Dizziness, Asthenia (weakness/fatigue), Constipation, Nausea
Uncommon (ge 0.1% to < 1%) Hypotension, Insomnia, Anxiety reactions

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions, while rare, are highlighted in official labeling and include Excessive Hypotension, Increased Angina and/or Myocardial Infarction (new or worsening chest pain), and Severe Allergic Reactions. Specific rare events, such as Gastrointestinal Obstruction associated with the extended-release tablet matrix, are also documented.

Nifedipine is subject to regulatory contraindications in patients with conditions such as Cardiogenic Shock and severe Hypotension. Furthermore, its safety profile includes specific warnings for certain populations, noting that the drug's exposure is higher in Older Adults and individuals with Hepatic Impairment due to reduced drug clearance. Time-related patterns indicate that dizziness and hypotension are more likely to occur at the beginning of treatment or during dose increases.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Nicardia (Nifedipine) is officially documented as a life-threatening medical emergency requiring immediate attention. The overdose profile is defined by profound hemodynamic instability and cardiac electrical disruption resulting from excessive calcium channel blockade.

Documented Overdose Manifestations

Manifestations listed in regulatory documents include severe hypotension (a severe drop in blood pressure), sinus node dysfunction, atrioventricular (AV) node dysfunction, reflex tachycardia, or bradycardia. Severe intoxication can lead to disturbances of consciousness, cardiogenic shock, myocardial infarction, and death.

Emergency Actions and Management

Immediate medical attention must be sought if an overdose is suspected or confirmed. Government guidelines mandate contacting emergency services (such as 911) if the patient collapses, has a seizure, or has trouble breathing. Management focuses on active cardiovascular support and monitoring, as no specific antidote is known. Officially described supportive measures include gastrointestinal decontamination (e.g., gastric lavage, activated charcoal) and the judicious use of calcium infusion and pressor agents. Patients who ingest a sustained-release formulation require prolonged observation for up to 12 hours due to the risk of delayed absorption. Nicardia clearance is expected to be prolonged in patients with impaired liver function.

Therapeutic Uses of Nicardia

Nicardia (Nifedipine) is generally used to help manage symptoms related to chronic cardiovascular conditions and vascular constriction. In clinical use, nifedipine is primarily prescribed for high blood pressure (hypertension) and used for managing angina (chest pain).

Managing Chronic High Blood Pressure and Angina

Nicardia is commonly used for the long-term management of conditions like hypertension, chronic stable angina, and vasospastic angina (Prinzmetal’s). This application helps to address the underlying physiological strain that may affect functional stability over time. The primary therapeutic benefit contributes to easing the overall symptom load related to systemic imbalance, assisting with maintaining stability during conditions marked by heightened physiological stress. Nicardia may also assist with easing the overall symptom burden related to recurrent chest discomfort, contributing to improved day-to-day comfort during symptomatic periods.

“This medication is relevant for managing conditions characterized by periods of heightened symptoms where supportive management of discomfort is needed.”

Support for Peripheral Circulation Issues

The medication is also considered relevant in managing conditions characterized by episodic digital ischemia, notably Raynaud’s phenomenon. This application is relevant when symptoms cluster into patterns of intense constriction in the small blood vessels of the extremities, often triggered by cold. The medication is applied in addressing these pronounced symptoms by assisting with easing the symptomatic discomfort in the fingers and toes, which supports the patient during difficult episodes by easing distress.

Quick Fact: Supportive Role in Managing Vascular Symptoms
Conditions Hypertension, Chronic Stable Angina, Raynaud's Phenomenon
Symptom Domains Elevated Systemic Pressure, Recurrent Chest Discomfort, Episodic Digital Ischemia
Primary Benefit Assists with maintaining functional stability and contributes to easing the overall symptom load

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Nicardia (Nifedipine) — Official Regulatory Information

Populations for whom use is contraindicated

Nicardia must not be used in patients with known hypersensitivity to Nifedipine or other dihydropyridines, or in those presenting with cardiogenic shock, unstable angina, or within one month of a myocardial infarction. The medicine is also contraindicated for patients taking the potent enzyme inducer Rifampin [Source 3.2]. Extended-release forms should not be used in patients with severe gastrointestinal narrowing.

Age-Related and Physiological Eligibility

  • Pediatric Use: Safety and efficacy have not been established in children and adolescents under 18 years of age; therefore, use is not recommended [Source 1.1].
  • Adult Use: The medicine is indicated for use in the adult population.
  • Older Adults: Eligible for use, but caution is necessary, and the immediate-release formulation should be avoided due to the risk of severe hypotension [Source 1.3].
  • Pregnancy/Lactation: Use is generally not recommended during lactation as the drug is excreted in breast milk. Regulatory status in pregnancy varies, with some authorities listing it as contraindicated [Source 2.3].

Conditional Use (Use with Caution)

Patients with hepatic impairment (liver problems) require special caution and close monitoring due to reduced drug clearance. Caution is also warranted for patients with severe hypotension or poor cardiac reserve [Source 1.1].

Connection to the overall eligibility profile: Regulatory documents define eligibility by permitting use primarily for the adult population while establishing mandatory exclusions (contraindications) for patients with acute cardiovascular instability or drug allergy. Eligibility is limited through cautions regarding hepatic impairment and by deeming use as not established or not recommended for the pediatric population and during lactation.

What should I know about interactions with other medicines?

Nicardia (Nifedipine) has documented interactions with other medicinal products and substances, primarily due to its metabolism by the Cytochrome P450 3A4 (CYP3A4) enzyme system.

Metabolism-Based Interactions

  • CYP3A4 Inhibitors (e.g., Cimetidine, some antifungals): Co-administration may increase Nicardia plasma concentrations, potentially leading to enhanced effects. Cautious dosage adjustment may be necessary.
  • CYP3A4 Inducers (e.g., Phenytoin, Phenobarbital, Rifampin, St. John’s Wort): These can significantly decrease Nicardia plasma concentrations by accelerating its metabolism, which may reduce its therapeutic effectiveness. The co-administration of Nicardia with strong inducers like Rifampin or St. John’s Wort is generally not recommended.

Interactions with Specific Products

  • Grapefruit Juice: Consumption of grapefruit or grapefruit juice must be avoided while taking Nicardia. Compounds in grapefruit inhibit CYP3A4 in the gut wall, which can dramatically increase the bioavailability and blood levels of Nicardia.
  • Other Antihypertensive Agents: Co-administration with other blood pressure-lowering medications, including Beta-blockers, may result in an additive hypotensive effect, which requires careful monitoring.
  • Digoxin: Nicardia can increase the plasma concentrations of Digoxin. Digoxin levels should be monitored when initiating, adjusting, or discontinuing Nicardia to mitigate the risk of Digoxin toxicity.
  • Immunosuppressants (e.g., Cyclosporine, Tacrolimus): Nicardia may increase the blood levels of these agents, necessitating frequent monitoring of their trough concentrations.

Mechanism of Action

Nicardia is an inhibitor of the L-type voltage-gated calcium channels (CaV1). Specifically, its active component, nifedipine, is a dihydropyridine antagonist that selectively targets these channels predominantly expressed on the cell membranes of vascular smooth muscle and myocardial cells.

The interaction consists of inhibition of calcium ion influx into the smooth muscle cell cytosol during the depolarization phase. This blockade of the calcium channel prevents the obligatory increase in intracellular calcium concentration that is necessary for the actin-myosin cross-bridge formation and subsequent contraction. The resulting intracellular pathway consequence is the suppression of smooth muscle contractile processes. At a system level, this leads to a reduction in peripheral arterial vascular resistance and dilation of coronary arteries, which collectively result in a reduction in systemic blood pressure and an increase in myocardial oxygen delivery.

Dosage and Administration Information

How to Use Nicardia: Official Administration Guidelines

Nicardia (Nifedipine) is officially administered via the oral route through two primary formulation types: immediate-release (IR) capsules and extended-release (ER) tablets. The specific dosing pattern is strictly dependent on the formulation used.


Official Dosing and Frequency Patterns

The immediate-release capsules are typically administered three to four times a day to maintain consistent levels. The adult dosing schedule for IR capsules generally begins at 10 mg three times daily, with maintenance doses ranging from 10 to 30 mg, up to a maximum of 180 mg per day. Conversely, the extended-release tablets are designed for administration once a day (q.d.). The ER starting dose is usually 30 mg or 60 mg once daily, with maintenance doses generally up to 90 mg per day.


Administration and Handling Constraints

The administration of the extended-release tablet is governed by specific physical handling constraints: the tablets must be swallowed whole and must not be crushed, chewed, or divided to ensure the controlled release mechanism is preserved. Regarding intake conditions, it is mandatory to avoid consuming grapefruit or grapefruit juice while on this medication, as this can affect the drug's concentration. Dose adjustments, if necessary, are typically performed at intervals of 7 to 14 days.


Population-Specific Considerations

Official labeling indicates that special procedural caution is required for patients with hepatic impairment; in such cases, treatment may require the consideration of the lowest available dose. Furthermore, the safety and efficacy of Nifedipine in the pediatric population (under 18 years of age) have not been established.

Recent Clinical Evidence

Nicardia: Recent Clinical Evidence

Nicardia (nifedipine) is a dihydropyridine calcium channel blocker widely studied for the management of hypertension (high blood pressure) and angina pectoris (chest pain). Clinical trials have primarily focused on the effectiveness and tolerability of its long-acting formulations.

Evidence for Hypertension and Angina

Research confirms that long-acting nifedipine formulations are associated with statistically significant reductions in both systolic and diastolic blood pressure in patients with mild to moderate essential hypertension. This effect is achieved by reducing total peripheral vascular resistance.

In the management of chronic stable angina, clinical studies demonstrated that nifedipine can lead to consistent improvements in exercise tolerance and time to onset of angina during controlled exercise tests. Long-acting formulations, which provide a controlled release, may help avoid the rapid, marked drop in blood pressure and reflex increase in heart rate sometimes seen with immediate-release versions.

Key Findings from Controlled Trials

Condition Studied Primary Effect Measured Findings from Trials
Essential Hypertension Change in blood pressure Demonstrated statistically significant reduction in both SBP and DBP.
Chronic Stable Angina Exercise time to onset of pain Showed consistent, significant improvement in exercise tolerance.

Long-Term Observations

Several studies have explored the effects of long-acting nifedipine beyond initial symptom control. Observations suggest that it may be associated with beneficial effects on endothelial function and arterial stiffness, which are factors related to cardiovascular health. Furthermore, clinical evidence supports its use in managing hypertensive disorders during pregnancy, citing comparable efficacy to other agents and a favorable maternal/fetal side-effect profile.

Key Studies & References

  1. ACOG Practice Bulletin No. 222: Gestational Hypertension and Preeclampsia

Frequently Asked Questions (FAQ)

Common questions about Nicardia (FAQ)


Q: What should I avoid eating or drinking when taking Nicardia?

According to official product information, it is advised to avoid consuming grapefruit or grapefruit juice while taking this medication. Compounds found in grapefruit can significantly increase the drug's concentration in the blood, which may lead to enhanced effects.


Q: Is Nicardia a once-a-day medication or does it need to be taken multiple times?

The required frequency depends entirely on the specific formulation prescribed. The immediate-release version often requires multiple doses daily, whereas the extended-release tablet is designed for once-daily use. The specific regimen is determined by the prescriber.


Q: Does Nicardia affect kidney function over time?

Special procedural caution and close monitoring are advised when treating individuals with more than mild kidney (renal) impairment. Use in individuals with kidney problems should be managed with caution and close monitoring by a healthcare provider.


Q: Can Nicardia be taken at night or is it better to take it in the morning?

Official prescribing information does not mandate a specific time of day for all formulations, only frequency. The most effective time to take the medication is determined during consultation with a healthcare provider, ensuring consistency with the prescribed regimen.


Q: Are there any long-term side effects associated with taking Nicardia for many years?

The safety data classifies side effects based on how frequently they were reported. Regulatory documents state that rare, serious adverse reactions, including excessive low blood pressure or worsening angina, have been reported. Long-term studies focus primarily on the drug's beneficial effects, such as on vascular health.


Q: Does Nicardia interact with herbal supplements like St. John's Wort?

Official labeling advises that co-administration with strong enzyme inducers like St. John’s Wort is generally not recommended. These supplements can accelerate the metabolism of the drug, which may reduce its intended effectiveness. Disclosure of all supplements and vitamins to a healthcare professional is standard practice.


Q: Can Nicardia be taken with common multivitamins?

Some authoritative sources suggest that taking Nicardia concurrently with certain multivitamin or mineral products may potentially decrease the drug's effectiveness. It is standard practice to inform a healthcare provider about all supplements and vitamins being used.


Q: Does Nicardia cause weight gain or loss?

The most common reported adverse effect is peripheral edema, which is fluid retention causing swelling in the ankles or feet. This fluid retention may result in perceived weight gain. Weight loss is not commonly listed as an adverse reaction.


Q: Are there specific symptoms that warrant calling a doctor immediately while on Nicardia?

Official warnings identify certain symptoms as serious adverse reactions, which include signs of excessive low blood pressure, new or worsening chest pain, or a severe allergic reaction, such as swelling or trouble breathing. These require immediate medical attention.


Q: How often do people need blood tests while taking Nicardia?

Routine blood monitoring is specifically recommended if the drug is taken with certain other medications, such as Digoxin or immunosuppressants, to check for increased levels of those co-administered drugs. The need for monitoring, beyond what is required for interacting medications, is based on a healthcare professional's assessment.


Q: What percentage of patients experience significant side effects from Nicardia?

Regulatory data classifies side effects by frequency from clinical trials. For example, Very Common side effects (ge 10%) include flushing and swelling (edema), while Common side effects (1% - <10%) include headache and dizziness. The complete list of reported effects is available in the official product information.


Q: Can Nicardia be taken by people with asthma or COPD?

Official regulatory documents do not list asthma or Chronic Obstructive Pulmonary Disease (COPD) as a specific contraindication or a condition requiring special warning for this medication. Use in individuals with these conditions is determined following consultation with a healthcare professional.


Q: What does 'vascular selectivity' mean in relation to Nicardia?

The drug's active ingredient is considered to be a highly selective calcium channel blocker. This means it primarily targets calcium channels located on the blood vessels (vascular smooth muscle) rather than the channels in the heart. This action leads to widening of the arteries.


Q: Why is the drug Nicardia sometimes formulated as a slow-release capsule?

The extended-release formulation is designed to provide a sustained and consistent release of the active ingredient over a longer period. This controlled release may help mitigate the potential for a rapid drop in blood pressure and reflex increase in heart rate sometimes seen with the immediate-release version.


Q: Is Nicardia safe for women who are planning to conceive?

The safety status of Nicardia during pregnancy varies among regulatory authorities, with some listing it as contraindicated. Official labeling advises that the potential risks and benefits for women who are planning to conceive or who are pregnant should be carefully considered with a healthcare provider.


Q: Does alcohol make Nicardia less effective or increase its side effects?

Authoritative patient information suggests that consuming alcohol may have additive effects with Nicardia, which could lead to further lowering of blood pressure. This may cause or worsen symptoms such as dizziness or lightheadedness.


Q: Is Nicardia safe for people with a history of heart failure?

The medication is contraindicated in patients with cardiogenic shock and should be used with caution in patients with poor cardiac reserve. Patients with a history of heart failure should be monitored, as the fluid retention caused by the drug may be confused with a worsening of their underlying condition.


Q: Why is Nicardia sometimes prescribed for Raynaud's phenomenon?

The drug's primary action is to widen blood vessels and reduce peripheral resistance. This mechanism makes it suitable for treating conditions that involve constricted or narrowed blood vessels, such as Raynaud's phenomenon.


Q: Is Nicardia a drug that needs to be tapered off gradually?

The product label notes that rare, serious adverse reactions have been reported during changes to treatment. Stopping blood pressure medication suddenly is generally not recommended. Any decision to stop or change the dosage should be made by a healthcare professional after a full evaluation.


Q: What are the most common side effects people report when they first start Nicardia?

The vasodilatory side effects are often more pronounced when the drug is first started or when the dosage is increased. These commonly include symptoms such as dizziness and a significant drop in blood pressure (hypotension).


Q: Is it true that Nicardia can cause a rapid heart rate (palpitations)?

Yes, palpitations, or an abnormal heartbeat, have been reported as a side effect. The drug's action of widening blood vessels can sometimes trigger a reflex increase in heart rate. It is important that any such symptoms are reported to a healthcare provider.

How should Nicardia be stored and disposed of?

Storage and Disposal Instructions for Nicardia

Nicardia (Nifedipine) requires specific storage and handling to maintain its stability and effectiveness, as documented in official regulatory labeling.

Required Storage Conditions

Condition Requirement
Temperature Store at a controlled room temperature, typically 20 C to 25 C.
Protection Protect from light and excess heat and moisture. Do not freeze the medication.
Container Keep the product in the original container and ensure it is tightly closed.
Safety Store strictly out of the sight and reach of children.

Disposal

Unused or expired Nicardia should not be flushed down the toilet. If a drug take-back program is unavailable, mix the medicine with an unappealing substance like dirt or coffee grounds, seal it in a container, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nicardia found in:

A-Z Index: